(Q48011694)

English

Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis

scientific article published in February 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

0 references

quality of life

1 reference

based on heuristic

inferred from title

randomized controlled trial

1 reference

based on heuristic

inferred from title

author name string

S R Feldman

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

A Menter

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

J Y Koo

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

language of work or name

0 references

publication date

1 February 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

150

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

317-326

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Psoriasis: current perspectives with an emphasis on treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

The outcomes movement and new measures of the severity of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Postal questionnaire study of disability in the community associated with psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.05697.X

21 January 2018

Identifiers

10.1111/J.1365-2133.2004.05697.X

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/14996104

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48011694&oldid=2181556519"